Merck & Co INC

FY2025 Health Issues as client

340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.

FY2025 Medicare/Medicaid as client

Drug Pricing. S.864 - HELP Copays Act.

S. 864

FY2025 Copyright/Patent/Trademark as client

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

FY2025 Health Issues as client

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

S. 2296 H.R. 3838 S. 891

FY2025 Medicare/Medicaid as client

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

H.R. 1

FY2025 Taxation/Internal Revenue Code as client

Issues related to tax reform; R&D tax credit; international taxation.

FY2025 Trade (domestic/foreign) as client

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

FY2025 Trade (domestic/foreign) as client

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

FY2025 Budget/Appropriations as client

H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.

H.R. 1

FY2025 Copyright/Patent/Trademark as client

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

FY2025 Health Issues as client

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

S. 2296 H.R. 3838 S. 891

FY2025 Medicare/Medicaid as client

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

FY2025 Taxation/Internal Revenue Code as client

Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21).

H.R. 1

FY2025 Health Issues as client

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues.

FY2025 Taxation/Internal Revenue Code as client

Tax policy impacting health care and pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act".

H.R. 1

FY2025 Medicare/Medicaid as client

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.

H.R. 1

FY2025 Pharmacy as client

General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues.

FY2025 Trade (domestic/foreign) as client

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

FY2025 Taxation/Internal Revenue Code as client

Issues related to international tax policy.

FY2025 Medicare/Medicaid as client

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform.

FY2025 Trade (domestic/foreign) as client

Issues related to intellectual property protections.

FY2025 Health Issues self-filed

H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).

H.R. 1 H.R. 1244 H.R. 1492 H.R. 1503 S. 2916 H.R. 1968 S. 1040 S. 1339 S. 2076

FY2025 Medicare/Medicaid self-filed

H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2026 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).

H.R. 1 H.R. 1244 H.R. 1492

FY2025 Taxation/Internal Revenue Code self-filed

Issues relating to, Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.

FY2025 Animals self-filed

Issues relating to, Agriculture; Animal Health; Animal Health Technology; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; United States Department of Agriculture, Animal and Plant Health Inspection Service, Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541-39,566, May 9, 2024).

FY2025 Taxation/Internal Revenue Code as client

Issues related to international tax policy.

FY2025 Health Issues as client

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. 340B. Vaccine access issues.

FY2025 Taxation/Internal Revenue Code as client

Tax policy impacting health care and pharmaceutical industry. OBBB.

FY2025 Medicare/Medicaid as client

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Implementation of IRA.

H.R. 1

FY2025 Pharmacy as client

General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues.

FY2025 Trade (domestic/foreign) as client

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

FY2025 Health Issues as client

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues.

FY2025 Taxation/Internal Revenue Code as client

Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.

FY2025 Medicare/Medicaid as client

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.

H.R. 1

FY2025 Medicare/Medicaid as client

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R.1, One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

H.R. 946 S. 1862 H.R. 1492 H.R. 1

FY2025 Taxation/Internal Revenue Code as client

H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes.

H.R. 1

FY2025 Trade (domestic/foreign) as client

Issues related to tariffs.

FY2025 Health Issues as client

Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.

FY2025 Medicare/Medicaid as client

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

FY2025 Taxation/Internal Revenue Code as client

Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act.

H.R. 1

FY2025 Trade (domestic/foreign) as client

Issues related to pharmaceutical IP, supply chain, and tariffs.

FY2025 Budget/Appropriations as client

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

H.R. 1

FY2025 Copyright/Patent/Trademark as client

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

FY2025 Health Issues as client

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

S. 891

FY2025 Health Issues as client

S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4); Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation

S. 891 H.R. 1968

FY2025 Medicare/Medicaid as client

Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946, ORPHAN Cures Act

H.R. 1672 H.R. 2484 H.R. 946

FY2025 Medicare/Medicaid as client

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

H.R. 4299

FY2025 Trade (domestic/foreign) as client

Issues related to intellectual property protections.

FY2025 Health Issues as client

Issues related to the Advisory Committee on Immunization Practices (ACIP).

FY2025 Medicare/Medicaid as client

Issues related to Medicare Part D and Part B Pricing Reform.

FY2025 Trade (domestic/foreign) as client

Issues related to intellectual property protections.

FY2025 Medicare/Medicaid as client

H.R.1 - One Big Beautiful Bill Act. H.R.1492: EPIC Act.

H.R. 1 H.R. 1492